Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection

Kato,Tomonori; Komiya,Akira; Morii,Akihiro; Iida,Hiroaki; Ito,Takatoshi; Fuse,Hideki

doi:10.3892/ol.2016.4693

Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection

Authors:
- Tomonori Kato
- Akira Komiya
- Akihiro Morii
- Hiroaki Iida
- Takatoshi Ito
- Hideki Fuse
View Affiliations

Affiliations: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama 930‑0194, Japan
Published online on: June 9, 2016 https://doi.org/10.3892/ol.2016.4693
Pages: 1132-1138

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Saturation prostate biopsy protocols have been developed to improve the prostate cancer (PCa) detection rate, particularly in the setting of repeat biopsies. The present study attempted to clarify the association between PCa detection and various risk factors in repeat saturation biopsies. A retrospective analysis was conducted on 78 Japanese patients for whom findings had caused suspicion of PCa despite previous negative prostate biopsies, and who consecutively underwent a 24‑core transperineal repeat biopsy at Toyama University Hospital (Toyama, Japan). PCa was confirmed histologically in 16 of the 78 patients (20.5%). A univariate analysis revealed that the prostate‑specific antigen (PSA) level at repeat biopsy was higher (P<0.01), the fPSA/tPSA ratio was lower (P=0.04), the total prostate volume was smaller (P=0.01) and the PSA density was higher (P<0.01) in PCa patients than in patients with benign prostatic disease (BPD). Histological inflammation was more frequently observed in BPD patients than in PCa patients (P<0.01). A multivariate analysis revealed that histological inflammation was the only independent predictor of the presence of a malignant lesion on repeat biopsy (odds ratio, 0.027; P=0.01). It must be considered that inflammation may cause a PSA increase in some patients with a negative initial biopsy, leading to unnecessary repeat biopsy.

View Figures

View References

1	Ouyang RC, Kenwright DN, Nacey JN and Delahunt B: The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy. BJU Int. 87:70–74. 2001. View Article : Google Scholar : PubMed/NCBI
2	Hodge KK, McNeal JE, Terris MK and Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 142:71–75. 1989.PubMed/NCBI
3	Rabbani F, Stroumbakis N, Kava BR, Cookson MS and Fair WR: Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 159:1247–1250. 1998. View Article : Google Scholar : PubMed/NCBI
4	Norberg M, Egevad L, Holmberg L, Sparèn P, Norlèn BJ and Busch C: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 50:562–566. 1997. View Article : Google Scholar : PubMed/NCBI
5	Pepe P and Aragona F: Prostate needle biopsy: 12 vs. 18 cores - is it necessary? Urol Int. 74:19–22. 2005.PubMed/NCBI
6	Ficarra V, Novella G, Novara G, Galfano A, Pea M, Martignoni G and Artibani W: The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol. 48:932–937. 2005. View Article : Google Scholar : PubMed/NCBI
7	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 360:1320–1328. 2009. View Article : Google Scholar : PubMed/NCBI
8	Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 360:1310–1319. 2009. View Article : Google Scholar : PubMed/NCBI
9	Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V, et al: Transrectal versus transperineal saturation rebiopsy of the prostate: Is there a difference in cancer detection rate? Urology. 77:921–925. 2011. View Article : Google Scholar : PubMed/NCBI
10	Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W and Wallner K: Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol. 52:715–723. 2007. View Article : Google Scholar : PubMed/NCBI
11	Borboroglu PG, Corner SW, Riffenburgh RH and Amling CL: Extensive repeat transrectal ultrasound-guided prostate biopsy in patient with previous benign sextant biopsies. J Urol. 163:158–162. 2000. View Article : Google Scholar : PubMed/NCBI
12	Stewart CS, Leibovich BC, Weaver AL and Lieber MM: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 166:86–92. 2001. View Article : Google Scholar : PubMed/NCBI
13	Morote J, Lopez M, Encabo G and de Torres IM: Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol. 37:537–540. 2000. View Article : Google Scholar : PubMed/NCBI
14	Kato T, Suzuki H, Komiya A, Imamoto T, Naya Y, Tobe T and Ichikawa T: Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. Int J Urol. 13:915–919. 2006. View Article : Google Scholar : PubMed/NCBI
15	Hellmann F, Verdi M, Schlemper BR Jr and Caponi S: 50th anniversary of the Declaration of Helsinki: The double standard was introduced. Arch Med Res. 45:600–601. 2014. View Article : Google Scholar : PubMed/NCBI
16	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL: ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
17	Krieger JN, Nyberg L Jr and Nickel JC: NIH consensus definition and classification of prostatitis. JAMA. 282:236–237. 1999. View Article : Google Scholar : PubMed/NCBI
18	Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC and Carter HB: Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol. 29:2185–2190. 2011. View Article : Google Scholar : PubMed/NCBI
19	Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 145:907–923. 1991.PubMed/NCBI
20	Kawakami S, Kihara K, Fujii Y, Masuda H, Kobayashi T and Kageyama Y: Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol. 11:613–618. 2004. View Article : Google Scholar : PubMed/NCBI
21	Shannon BA, McNeal JE and Cohen RJ: Transition zone carcinoma of the prostate gland: A common indolent tumor type that occasionally manifests aggressive behaviour. Pathology. 35:467–471. 2003. View Article : Google Scholar : PubMed/NCBI
22	Zaytoun OM, Moussa AS, Gao T, Fareed K and Jones JS: Office-based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 186:850–854. 2011. View Article : Google Scholar : PubMed/NCBI
23	Bastian PJ, Mangold LA, Epstein JI and Partin AW: Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer. 101:2001–2005. 2004. View Article : Google Scholar : PubMed/NCBI
24	Epstein JI, Sanderson H, Carter HB and Scharfstein DO: Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology. 66:356–360. 2005. View Article : Google Scholar : PubMed/NCBI
25	Gann PH, Fought A, Deaton R, Catalona WJ and Vonesh E: Risk factors for prostate cancer detection after a negative biopsy: A novel multivariable longitudinal approach. J Clin Oncol. 28:1714–1720. 2010. View Article : Google Scholar : PubMed/NCBI
26	Djavan B, Fong YK, Ravery V, Remzi M, Horninger W, Susani M, Kreuzer S, Boccon-Gibod L, Bartsch G and Marberger M: Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A multi-institutional prospective European study. Eur Urol. 47:38–44. 2005. View Article : Google Scholar : PubMed/NCBI
27	Brawer MK: The influence of prostate volume on prostate cancer detection. Eur Urol Suppl. 1:35–39. 2002. View Article : Google Scholar
28	Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, et al: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol. 55:600–606. 2009. View Article : Google Scholar : PubMed/NCBI
29	Sajadi KP, Kim T, Terris MK, Brown JA and Lewis RW: High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology. 70:691–695. 2007. View Article : Google Scholar : PubMed/NCBI
30	Oderda M and Gontero P: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: Is repeat biopsy still necessary? BJU Int. 104:1554–1556. 2009. View Article : Google Scholar : PubMed/NCBI
31	Inahara M, Suzuki H, Nakamachi H, Kamiya N, Shimbo M, Komiya A, Ueda T, Ichikawa T, Akakura K and Ito H: Clinical evaluation of transrectal power doppler imaging in the detection of prostate cancer. Int Urol Nephrol. 36:175–180. 2004. View Article : Google Scholar : PubMed/NCBI
32	Chan TY and Epstein JI: Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology. 53:351–355. 1999. View Article : Google Scholar : PubMed/NCBI
33	Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: European Association of Urology: EAU guidelines on prostate cancer. Eur Urol. 53:68–80. 2008. View Article : Google Scholar : PubMed/NCBI
34	Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:909–916. 1987. View Article : Google Scholar : PubMed/NCBI
35	Yaman O, Göğüş C, Tulunay O, Tokatli Z and Ozden E: Increased prostate-specific antigen in subclinical prostatitis: The role of aggressiveness and extension of inflammation. Urol Int. 71:160–164. 2003. View Article : Google Scholar : PubMed/NCBI
36	Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W and Van Marck E: Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: Correlation with total serum PSA and PSA density. Eur Urol. 37:404–412. 2000. View Article : Google Scholar : PubMed/NCBI
37	Kandirali E, Boran C, Serin E, Semercioz A and Metin A: Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology. 70:743–747. 2007. View Article : Google Scholar : PubMed/NCBI
38	Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A and Fujisawao M: Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10–50 ng/ml. Urology. 72:1194–1197. 2008. View Article : Google Scholar : PubMed/NCBI